Table 3.
Overall and study visit adherence and agreement results for 6-OH-buspirone, pill count and medication diary for the study cohort randomized to receive buspirone during treatment (n=58).
| Study Visit | Adherence Measurement | Agreement Statistics | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pill Counta | Diarya | Riboflavinb | 6-OH Buspironec | Pill Count/Buspirone | Diary/Buspirone | Riboflavin/Buspirone | |||||||||
|
|
|||||||||||||||
| N | Mean (SD) | % Comp | Mean (SD) | % Comp | Mean (SD) | % Comp | Mean (SD) | % Comp | % Agree | Kappa | % Agree | Kappa | % Agree | Kappa | |
| Visit 2 | 50 | 92.6 (12. 1) | 87.8 % | 93.8 (11. 8) | 87.5 % | 3755 (2603) | 84.0 % | 10.0 (9.4) | 78.0 % | 77.6 % | 0.55 | 77.1 % | 0.54 | 94.0 % | 0.88 |
| Visit 4 | 38 | 87.8 (16. 0) | 76.3 % | 89.9 (15. 5) | 83.8 % | 4257 (2551) | 86.8 % | 9.9 (10. 2) | 81.6 % | 63.2 % | 0.26 | 73.0 % | 0.46 | 89.5 % | 0.79 |
| Visit 6 | 36 | 94.6 (8.0) | 88.9 % | 96.0 (5.8) | 100 % | 3672 (2605) | 83.3 % | 10.5 (10. 1) | 75.0 % | 75.0 % | 0.50 | 73.5 % | 0.47 | 80.6 % | 0.61 |
| Visit 8 | 35 | 95.0 (13. 2) | 88.6 % | 94.8 (13. 6) | 88.6 % | 4105 (3035) | 74.3 % | 10.5 (13. 6) | 80.0 % | 74.3 % | 0.49 | 74.3 % | 0.49 | 94.3 % | 0.89 |
| Visit 10 | 34 | 92.4 (18. 6) | 87.9 % | 94.7 (12. 0) | 91.2 % | 2845 (2550) | 70.6 % | 8.1 (8.8) | 73.5 % | 63.6 % | 0.27 | 64.7 % | 0.29 | 73.5 % | 0.47 |
| Visit 12 | 32 | 96.5 (8.9) | 90.3 % | 96.2 (8.8) | 93.1 % | 2556 (2524) | 56.3 % | 4.4 (5.8) | 53.1 % | 45.2 % | − 0.10 | 44.8 % | − 0.10 | 65.6 % | 0.31 |
| Overall | 93.0 (14. 1) | 86.5 % | 94.1 (11. 9) | 90.3 % | 3573 (2686) | 76.9 % | 9.0 (10. 0) | 74.2 % | 67.6 % | 0.35 | 69.1 % | 0.38 | 84.0 % | 0.68 | |
Pill count and Diary data are shown as mean (SD) proportion of study doses taken as a function of the number of study doses prescribed. Percent compliant (% Comp) is shown as the proportion of participants with ≥ 80% of study doses taken at that visit.
Riboflavin data are shown as the mean (SD) ng/ml of riboflavin detected at each visit. Percent complaint is shown as the proportion of participants with ≥ 900 ng/ml riboflavin detected at that visit.
6-OH-buspirone data are shown as the mean (SD) ng/ml of the metabolite detected at each visit. Percent complaint is shown as the proportion of participants with > 0 ng/ml detected at that visit. The Prevalence and Bias Adjusted Kappa (PABAK) is shown.